Optimization of Cardiac-MR Protocols

December 18, 2011 updated by: Ursula Reiter, Medical University of Graz

Optimization of Native Cardiac-MR Protocols

The aim of the present study is the optimization of various magnetic resonance (MR) investigation protocols of the heart and the lung without contrast agent application as well as the generation of normal values from cardiac MR images. One of the main problems in cardiac MR investigations is the strong dependence of the achieved image quality on optimal settings of sequence parameters and anatomical and physiological situations with special emphasis on phase-contrast imaging and other cine-techniques.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Time optimized and well organized MR protocols for the cardiac and lung investigations are evaluated on normal subjects with special respect to following topics:

  1. Localization: Definition of standardized anatomic imaging planes with special respect to the right ventricle.
  2. Morphological imaging: Optimization of spin-echo and gradient-echo sequences for various heart frequencies and breath-hold abilities. Investigation of the effect of various preparation pulses. Optimization of the signal-to-noise ratio for morphological cardiac imaging. Evaluation and optimization of various breathing and breath-hold (with and without navigator) ECG and pulse triggered sequences.
  3. Cardiac and lung function: Optimization of gradient-echo sequences for various heart frequencies and breath-hold abilities. Evaluation of pulse-triggered function analysis and optimization of free breathing protocols. Optimization of tagging techniques. Evaluation of the pulsatile flow in lung vessels. Acquisition of age depended normal data of cardiac and lung function.
  4. Coronary imaging: Definition of standardized anatomic imaging planes to monitor coronary arteries (single oblique, volume targeted). Optimization of acquisition window with respect to various heart frequencies. Evaluation of the influence of the position of the navigator and tracking factor on image quality. Optimization of a pulse triggered protocol. Evaluation of black-blood coronary imaging and visualization of the lumen and wall of coronary arteries.
  5. Phase contrast techniques: Optimization of imaging planes, time resolution and spatial resolution of flow measurements in the heart, in the vessels around the heart, lung vessels and coronary arteries. Evaluation of retrospective and prospective gating with respect to the heart frequency. Evaluation of normal values in 1-dimensional, 2-dimensional and 3-dimensional time resolved flow measurements.
  6. Single-Shot Imaging: Evaluation of signal intensity and stability of single shot techniques with and without preparation pulses. Optimization of real-time image acquisition.
  7. Parallel acquisition and breath-hold time optimization: Evaluation of impact of echo-sharing and parallel acquisition on image quality. Optimization of short-breath-hold protocols.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
122

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
    • Stmk
      • Graz, Stmk, Austria, 8036
        • Medical Unitersity Graz, Allgemeine Radiologische Diagnostik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

healthy volunteers

Description

Inclusion Criteria:

  • No history of cardiac or pulmonary diseases

Exclusion Criteria:

  • MRI exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Medical University of Graz

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Gert Reiter, DI Dr., Siemens Medical Solutions
  • Principal Investigator: Ursula Reiter, DI Dr., University Hospital Graz

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2002

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2011

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 1, 2011

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 13, 2007

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 13, 2007

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 14, 2007

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 20, 2011

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 18, 2011

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2011

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CMR-02-TECH-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings